Financial Survey: Positron (POSC) and Its Rivals

Positron (OTCMKTS:POSCGet Free Report) is one of 71 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare Positron to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings for Positron and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Positron 0 0 0 0 N/A
Positron Competitors 266 798 1967 59 2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,107.40%. Given Positron’s peers higher probable upside, analysts clearly believe Positron has less favorable growth aspects than its peers.

Profitability

This table compares Positron and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Positron -300.00% N/A -89.57%
Positron Competitors -341.23% -95.28% -31.21%

Institutional and Insider Ownership

44.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by insiders. Comparatively, 13.2% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Positron has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Positron’s peers have a beta of 1.02, meaning that their average share price is 2% more volatile than the S&P 500.

Valuation and Earnings

This table compares Positron and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Positron $740,000.00 -$1.64 million -11.75
Positron Competitors $1.06 billion $88.76 million -8.38

Positron’s peers have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Positron peers beat Positron on 7 of the 10 factors compared.

About Positron

(Get Free Report)

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.